# Loss of Myonuclei and Transcriptional Activity During Diaphragm Atrophy in Critically Ill Patients

**Authors:** Wout J. Claassen, Marloes van den Berg, Zhong Hua Shi, Rianne. J. Baelde, Sylvia Bogaards, Luuk Bonis, Heleen Hakkeling, Arezou Bamyani, Gerben J. Schaaf, Albertus Beishuizen, Chris Dickhoff, Reinier A. Boon, Leo Heunks, Tyler J. Kirby, Coen A. C. Ottenheijm

PMC · DOI: 10.1002/jcsm.70228 · 2026-02-15

## TL;DR

This study finds that critically ill patients experience a loss of myonuclei and reduced transcriptional activity in their diaphragm muscles, contributing to muscle weakness unrelated to the duration of mechanical ventilation.

## Contribution

The study identifies intrinsic apoptotic pathway activation as a novel mechanism for myonuclear loss in diaphragm atrophy among ICU patients.

## Key findings

- Myonuclear number and domain size are significantly reduced in critically ill patients with diaphragm atrophy.
- Apoptotic myonuclei and activated caspase-3 are increased in ICU patients with atrophy.
- Transcriptional activity and muscle stem cell numbers decrease in patients with diaphragm atrophy.

## Abstract

Diaphragm weakness frequently develops in critically ill patients and is explained by a combination of atrophy and myofiber dysfunction. Myofibers are large syncytial cells maintained by a population of myonuclei, which provide gene transcripts to a finite fiber volume, termed the myonuclear domain. Myonuclear number is a determinant of transcriptional capacity and therefore critical for diaphragm and peripheral muscle regeneration after critical illness. Changes in myonuclear number in myofibers undergoing atrophy have not been investigated in mechanically ventilated ICU patients, but they are of potential clinical importance. Our objective was to investigate if and how myonuclear number changes in the diaphragm of mechanically ventilated ICU patients and whether changes are associated with myofiber atrophy and clinical parameters.

We used a combination of transcriptomics, immunohistochemistry and confocal microscopy to study myonuclear alterations in the diaphragm and quadriceps biopsies from mechanically ventilated ICU patients (n = 24) and non‐critically ill patients (n = 10).

Compared to control patients, myonuclear number and myonuclear domain were reduced in critically ill patients with diaphragm myofiber atrophy (n = 14) (myonuclear number per mm of 133 [92–183] vs. 92 [83–105], p = 0.03 (slow myofibers) and 149 [118–189] vs. 88 [69–109], p = 0.004 (fast myofibers); myonuclear domain size was 44 [34–51] vs. 29 pL, p = 0.004 (slow myofibers) and 41 [39–48] vs. 27 pL, p = 0.001 (fast myofibers) of control patients and ICU patients with atrophy, respectively). Increased intrinsic apoptotic pathway activation was identified as a mechanism underlying myonuclear removal (percentage of apoptotic myonuclei of 0.64 [0.60–0.84] and 0.95 [0.84–1.2], p = 0.015 and increased percentage of activated caspase‐3 positive myonuclei of 2,5 [1.6–3.3] vs. 5.7 [4.3–11], p = 0.001 in control patients and ICU patients with atrophy, respectively). Total transcriptional activity in myofibers decreased with myonuclear loss (RNA‐Pol‐2 Ser5 fluorescence intensity per fibre of 2.6 [2.2–3.3] vs. 5.8 [3.1–6.7] AU, p = 0.036 in control patients and ICU patients with atrophy, respectively). Furthermore, muscle stem cell number was reduced in the patients with diaphragm atrophy (PAX7 positive nuclei per myofiber of 0.10 [0.09–0.11] vs. 0.05 [0.04–0.07], p = 0.002 in control patients and ICU patients with atrophy, respectively). No correlation was found between myonuclear loss and duration or mode of mechanical ventilation.

We identified myonuclear loss due to intrinsic apoptotic pathway activation as a potential mechanism underlying diaphragm atrophy in mechanically ventilated patients. The loss of myonuclei may contribute to impaired regeneration of myofibers after critical illness. Duration and mode of mechanical ventilation are not the major drivers of these modifications.

## Linked entities

- **Proteins:** PAX7 (paired box 7), Polr2A (RNA polymerase II subunit A), Casp3 (caspase 3)

## Full-text entities

- **Genes:** PAX7 (paired box 7) [NCBI Gene 5081] {aka CMYO19, CMYP19, HUP1, MYOSCO, PAX7B, RMS2}, DNTT (DNA nucleotidylexotransferase) [NCBI Gene 1791] {aka TDT}, PCM1 (pericentriolar material 1) [NCBI Gene 5108] {aka PTC4, RET/PCM-1}, DMD (dystrophin) [NCBI Gene 1756] {aka BMD, CMD3B, DXS142, DXS164, DXS206, DXS230}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, FADD (Fas associated via death domain) [NCBI Gene 8772] {aka GIG3, IMD90, MORT1}
- **Diseases:** weight loss (MESH:D015431), Chronic Kidney Disease (MESH:D051436), Atrophy (MESH:D001284), pulmonary nodule (MESH:D055613), atrophic (MESH:D020966), weaning failure (MESH:D051437), CKD (MESH:D012080), lung malignancy (MESH:D008175), Diaphragm weakness (MESH:D018908), Brain (MESH:D001927), physical disability (MESH:D059445), mitochondrial dysfunction (MESH:D028361), long-term impairment (MESH:D000088562), muscle atrophy (MESH:D009133), Inflammatory (MESH:D007249), myonuclear loss (MESH:D016388), Critically Ill (MESH:D016638), myonuclear apoptosis (MESH:D065703), neuromuscular blockade (MESH:D020879), pulmonary hypertension (MESH:D006976), Chronic Inflammatory Disease (MESH:D002908), metabolic disorders (MESH:D008659), neuromuscular diseases (MESH:D009468), CSA (MESH:D003057), COPD (MESH:D029424), myofiber dysfunction (MESH:D006331), Diaphragm (MESH:D065630), Type 2 Diabetes Mellitus (MESH:D003924), congestive heart failure (MESH:D006333)
- **Chemicals:** dUTP (MESH:C027078), oxygen (MESH:D010100), phalloidin (MESH:D010590), DAPI (MESH:C007293), steroids (MESH:D013256)
- **Species:** Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907519/full.md

---
Source: https://tomesphere.com/paper/PMC12907519